2025-522039-33-00招募中2 期
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis
Leal Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2026年1月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Incidence and severity of AEs, TEAEs and SAEs
研究概览
简要总结
To evaluate the safety and tolerability of intrathecally (IT) administered LTX-002 in adult participants with amyotrophic lateral sclerosis (ALS) compared to placebo.
研究设计
- 分配方式
- Not Applicable
- 主要目的
- Follow-up period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •The participant is a male or female, 18 to 75 years of age, inclusive, at the time of consent.
- •Female participants of childbearing potential with male partners, and male participants with female partners of child-bearing potential must be willing to use two effective methods of contraception (with at least one being highly effective) from Day 1 until 3 months after their last dose of study drug.
- •The participant has a diagnosis of ALS per Gold Coast criteria.
- •The participant had ALS symptom onset less than 36 months prior to Screening.
- •The participant is capable of providing informed consent. Both of the following criteria must be met: a. The participant must be fluent (oral and written) in the local language to consent. b. An informed consent form (ICF) must be signed by the participant before any study assessments are performed. c. If the participant is able to comprehend and is willing to sign the ICF, but cannot physically sign the ICF, an impartial witness must sign the ICF.
- •An SVC ≥ 50% of predicted value as adjusted for sex, age, and height (from the sitting position).
- •If taking riluzole, edaravone, or sodium phenylbutyrate + taurursodiol, participants must be on a stable dose for ≥ 30 days prior to Day 1 and be expected to remain at that dose until the final study visit (Day 169).
- •Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the PI.
- •Screening values of coagulation parameters including platelet count, International Normalization Ratio, prothrombin time, and activated partial thromboplastin time should be within normal ranges.
- •Body mass index ≥18 and ≤40 kg/m2
排除标准
- •Current evidence or history of a clinically significant medical condition, including clinically meaningful frailty as determined by the Investigator, or an abnormal laboratory value that, in the Investigator’s judgement, would impact the participant’s safety, interpretation of study results, or place the participant at high risk of poor treatment compliance or of not completing the study. This includes significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, and neurologic disease.
- •Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter.
- •Presence of any implanted vascular devices, including but not limited to pacemakers, vascular stents and prosthetic heart valves.
- •Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that is not managed optimally and could place a participant at an increased risk for intraoperative or postoperative bleeding. These could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand’s disease, liver disease).
- •Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication (e.g., clopidogrel, apixaban) for 7 days before or 48 hours after an LP. Low-dose (≤81mg daily) aspirin for cardiovascular prophylaxis is allowed.
- •Confirmed coronavirus disease 2019 (COVID-19) or positive influenza test within 4 weeks prior to Day
- •Regional and site COVID-19 testing policies should be followed throughout the study.
- •History of a positive test result for human immunodeficiency virus (HIV) or is positive at Screening.
- •Acute or chronic hepatitis C infection (defined as positive hepatitis C virus [HCV] antibody and detectable HCV RNA).
- •Acute or chronic hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg]). Participants with immunity to hepatitis B from previous natural infection or vaccination (defined as negative HBsAg, positive hepatitis B surface antibody, ± anti-hepatitis B core antigen [HbcAg]) are eligible to participate in the study.
- •Diagnosis of moderate to severe substance use disorder per DSM-5 criteria (except tobacco use disorder) within the 12 months before Screening (confirmed at Screening), or current abuse as determined by urine toxicology screen. Cannabis is allowed if a) it is legal in the region where the participant resides AND b) it would not, in the investigator’s judgment, interfere with the participant’s ability to comply with the requirements in the protocol.
- •At risk for suicidal behavior during the study as determined by the investigator’s clinical assessment and Columbia Suicide Severity Rating Scale (C-SSRS) as confirmed by the following: a. Answers “Yes” on items 4 or 5 (C-SSRS – ideation) with the most recent episode occurring within the 2 months before Screening, OR b. Answers “Yes” to any of the 5 items (C-SSRS-behavior) with an episode occurring within the 12 months before Screening. Non-suicidal self-injurious behavior is not exclusionary.
- •History of cancer, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin and cervical cancer.
- •Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
- •Donated blood or blood products >450 mL within 30 days before study drug administration.
- •History of relevant drug allergies (i.e., allergy to any study drug or excipients, to a broad range of anesthetics)
- •History of brain or spinal abnormalities on magnetic imaging (MRI) or computed tomography that might interfere with the LP, CSF circulation or safety assessments, such as subarachnoid hemorrhage, suggestion of raised intracranial pressure on MRI or ophthalmic examination, spinal stenosis or curvature, spina bifida occulta, a Chiari malformation, hydrocephalus, syringomyelia, tethered spinal cord syndrome, frontotemporal brain sagging syndrome and connective tissue disorders such as Ehlers Danlos and Marfan Syndromes.
- •12-lead electrocardiogram (ECG) demonstrating left bundle branch block or corrected QT interval by Fridericia’s formula (QTcF) >450 milliseconds for men and >460 milliseconds for women. In participants with right bundle branch block, a QT interval of up to 480 milliseconds may be allowed after consultation with the medical monitor. If QTcF exceeds 450 milliseconds for men and >460 milliseconds for women, the ECG should be repeated 2 more times and the average of the 3 QTcF values should be used to determine the participant’s eligibility.
- •ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and confirmed by a single repeat, if deemed necessary: a. Serum creatinine level more than 1.5-fold above the upper limit of normal (ULN) or an estimated glomerular filtration rate value <60 mL/min/1.73 m2 calculated with the “2021 Chronic Kidney Disease Epidemiology Collaboration formula for Estimated Glomerular Filtration Rate” or urine albumin to creatinine ratio of >300 mg/g at Screening. b. Alanine transaminase, aspartate aminotransferase or bilirubin ≥1.5 × ULN or history of portal hypertension. Participants with known Gilbert Syndrome and elevated bilirubin may participate.
- •Treatment with another investigational drug (including investigational drugs for ALS through compassionate use programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer, before Screening
- •Prior treatment with ASO, small interfering ribonucleic acid (RNA), stem cell therapy, or gene therapy for any indication.
- •Current or anticipated need, in the opinion of the Investigator, of a diaphragmatic pacing system during the study period.
- •Tracheostomy.
结局指标
主要结局
Incidence and severity of AEs, TEAEs and SAEs
Incidence and severity of AEs, TEAEs and SAEs
Clinical laboratory tests (serum chemistry and hematology; urinalysis)
Clinical laboratory tests (serum chemistry and hematology; urinalysis)
ECGs
ECGs
Vital signs (blood pressure, heart rate, respiratory rate, body temperature)
Vital signs (blood pressure, heart rate, respiratory rate, body temperature)
Physical and neurological exams.
Physical and neurological exams.
次要结局
- CSF levels of LTX-002
- Single-dose plasma PK parameters for the first and last of the three doses, including Cmax, Tmax, AUC0-t, AUC0-∞, Tlag if applicable, Vd/F, λz, T1/2, and CL/F
- Where data are available, AUC0-∞ AUC0 t, and Cmax will be tested for dose proportionality using a power model approach.
研究者
Lawrence Severt
Scientific
Leal Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)Part A: Healthy volunteers (Part A is not applicable to the EU; for information only)
Part B: pulmonary arterial hypertension2024-513613-12-00Novartis Pharma AG68
招募中
2 期
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic PainDiabetic Peripheral Neuropathic PainNCT07285018Eli Lilly and Company150
招募中
2 期
A Phase 2b Clinical Study to Evaluate the Safety and Efficacy of Topical Administration of
Bacteriophage Therapy TP-102 in Patients with Diabetic Foot InfectionDiabetic foot ulcers infected by Acinetobacter baumannii, Pseudomonas aeruginosa and /or Staphylococcus aureus2023-507716-13-00Technophage Investigacao E Desenvolvimento Em Biotecnologia S.A.26
招募中
2 期
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)Diffuse Cutaneous Systemic SclerosisNCT07287670Mediar Therapeutics85
已完成
1 期
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult VolunteersHealthy VolunteersNCT07279636AlphaMol Science Ltd. (Shanghai)55